KLRB1 and neoplasm: Nevertheless, CD276 has been confirmed to be overexpressed in many tumor types, and the prevailing opinion is that CD276 supports glioma progression and should be considered as an important target for glioma therapy, which is also true for natural killer receptor protein 1 (CD161) overexpressed in gliomas [13,14,21].